BioLineRx Presents BL-1040 Data at the American Heart Association Scientific Sessions 2007
"These data support our previous findings that BL-1040 has the potential to contribute to a more complete recovery of patients who have suffered from severe heart attacks," stated Morris C. Laster, MD, chief executive officer of BioLineRx. "We look forward to beginning a multi-center, open label Phase 1/2 study of BL-1040 as soon as we receive regulatory approval."
BL-1040 is a resorbable liquid polymer intended to provide mechanical support to damaged heart tissue following an acute MI. BL-1040 is injected via the coronary artery during catheterization as a liquid that polymerizes within damaged heart tissue and forms a protective scaffold that enhances the mechanical strength of the heart muscle during recovery and repair. This scaffold prevents the pathological enlargement of the left ventricle that occurs following a heart attack and improves cardiac function. BL-1040 is naturally excreted from the body within six weeks of injection.
Patients who have undergone an acute MI (AMI) with severe heart damage are the most likely to benefit from BL-1040. Approximately 40% of AMI patients develop left ventricle dilatation or heart failure, which carries a substantially greater mortality risk.
BL-1040 was in-licensed from Ben-Gurion University through its business company BGN Technologies, and was developed by Professor Smadar Cohen and Professor Jonathan Leor from the Department of Biotech and Biomedical Engineering at Ben-Gurion University.
BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.
BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials. BioLineRx partners with researchers, universities and biotech companies to further the commercialization of promising compounds. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd., venture capital firms Giza Venture Capital and Pitango Venture Capital, and Hadasit, the technology transfer company of Hadassah Hospital and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.
This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "look forward," and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.
Yuri Shoshan, +972-2-548-9100
VP Finance and Corporate Development
Stern Investor Relations, Inc.
Melanie Friedman, 212-362-1200
Media Liaison, BioLineRx Ltd.
Tsipi Haitovsky, +972-52-598-9892
Posted: November 2007